The gene panel market sits at the core of precision diagnostics, enabling simultaneous analysis of multiple genes linked to specific diseases. It is a critical enabler of targeted therapy selection, risk assessment, and increasingly, population‑level screening strategies.

The market was valued at approximately USD 6.8 billion in 2023, around USD 7.67 billion in 2024, and is projected to reach about USD 20.1 billion by 2032, growing at a CAGR of roughly 12.8%. Growth is underpinned by the rising prevalence of genetic disorders, rapid advances in sequencing technologies, and the broader shift toward personalized medicine across oncology, cardiology, neurology, and infectious diseases.

Oncology is the largest application segment, with gene panels used for tumor profiling, hereditary cancer risk assessment, and therapy selection. Cardiology and neurology panels are expanding as genetic contributions to arrhythmias, cardiomyopathies, epilepsy, and neurodegenerative diseases become better understood and clinically actionable. Infectious disease panels are also gaining traction, particularly for rapid pathogen identification and resistance profiling.

Next‑generation sequencing (NGS) dominates the technology landscape due to its high throughput, falling costs, and ability to analyze many genes in a single run. Sanger sequencing remains relevant for confirmatory testing and smaller panels, while microarray technologies continue to support specific applications such as copy‑number variant detection.

Product types include targeted panels (focused on a defined set of genes), expanded panels (broader gene sets for complex conditions), and exome panels (covering protein‑coding regions). Targeted panels are widely used in routine clinical practice for well‑characterized conditions, while expanded and exome panels are increasingly deployed when initial testing is inconclusive or phenotypes are atypical.

Hospitals and diagnostic laboratories are the primary end users, supported by academic and research institutes that drive method development and validation. North America leads the market, followed by Europe, with Asia‑Pacific expected to grow rapidly as sequencing capacity, regulatory frameworks, and awareness of genetic testing improve.

Major players include Roche, Illumina, Qiagen, Thermo Fisher Scientific, Agilent, Myriad Genetics, Invitae, Exact Sciences, BGI, and others, with competition focused on panel design, turnaround time, analytical validity, clinical interpretation, and integration with electronic health records and decision‑support tools.

Read more: Global Gene Panel Market Research Report

People Also Ask

Q1. What is a gene panel test used for?
A gene panel test analyzes a selected set of genes associated with a particular disease or group of conditions to identify pathogenic variants that may explain a patient's symptoms, predict disease risk, or guide treatment choices. It is commonly used in oncology for tumor profiling and hereditary cancer risk, in cardiology for inherited heart conditions, in neurology for epilepsy and neurodegenerative disorders, and in infectious disease for pathogen detection.

Q2. How is a gene panel different from whole‑genome sequencing?
A gene panel focuses on a predefined list of genes relevant to a specific clinical question, making it faster, cheaper, and easier to interpret for that indication. Whole‑genome sequencing reads nearly the entire DNA sequence, capturing both coding and non‑coding regions, which provides broader information but at higher cost, with more complex data analysis and interpretation challenges. Gene panels are often preferred when the clinical suspicion is focused on particular conditions.

Tags: gene panel market, genetic testing, precision medicine, NGS panels, oncology diagnostics, personalized healthcare